Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma
Cell surface PTGFRN is a candidate target for intracranial CAR-T cell therapy for GBM. On-target off-tumor toxicity in alternative normal tissues needs to be carefully tested.
Authors
- Tetsuro Tachi
- Reina Utsugi
- Koki Murakami
- Haruhiko Kishima (ORCID: https://orcid.org/0000-0002-9041-2337)
- Ryuichi Hirayama (ORCID: https://orcid.org/0000-0002-3739-6219)
- Naoki Hosen (ORCID: https://orcid.org/0000-0001-9570-0947)
- Noriyuki Kijima (ORCID: https://orcid.org/0000-0003-2103-1909)
- Shunya Ikeda (ORCID: https://orcid.org/0000-0002-1866-2155)
- Yoshiko Okita (ORCID: https://orcid.org/0000-0002-2943-238X)
- Moto Yaga (ORCID: https://orcid.org/0000-0001-6649-6887)
- Hideki Kuroda
- Kanji Nakagawa
- N. Kagawa
- Tomoyoshi Nakagawa
Institutions
- Osaka City General Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1007/s00262-025-03979-4
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Takeda Science Foundation
- Uehara Memorial Foundation
- Osaka University
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Japan Brain Foundation
- Japan Society for the Promotion of Science